Israel's Kamada to get $45 million from distribution deal with Baxter for Glassia in North America and Australia/NZ

26 August 2010

Israeli biopharmaceutical firm Kamada (KMDA: IT) has entered into an exclusive distribution and manufacturing agreement with US company Baxter International (NYSE: BAX), for Kamada's liquid, ready to use, intravenous alpha-1 antitrypsin product for the treatment of hereditary alpha-1 antitrypsin deficiency approved by the US Food and Drug Administration on July 1, for marketing under the trade name Glassia.

The companies have also entered into a technology sharing agreement for the manufacturing of liquid AAT at Baxter's facility using Kamada's proprietary and patented technology.

Baxter commits to minimum purchase quantity of $60 million over five years

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK